Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 13/20 | 0.42 |
| ▸ | CTSL | P07711 | 11/20 | 0.42 |
| ▸ | CTSS | P25774 | 10/20 | 0.42 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 3/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747702 | 0.92 | CTSL (0.44) | CTSBCTSLCTSSCTSKL3MBTL1 | |
| SCHEMBL6747828 | 0.92 | CTSL (0.47) | CTSBCTSLCTSSCTSKHPGDS | |
| SCHEMBL6751639 | 0.90 | CTSL (0.50) | CTSBCTSLCTSSCTSKL3MBTL1 | |
| SCHEMBL6747732 | 0.90 | CTSL (0.40) | CTSBCTSLCTSSCTSKHPGDS | |
| SCHEMBL6752286 | 0.90 | CTSL (0.51) | CTSBCTSLCTSSCTSKHPGDS | |
| SCHEMBL6751875 | 0.90 | CTSB (0.46) | CTSBCTSLCTSSCTSKHPGDS | |
| SCHEMBL6988397 | 0.89 | CTSL (0.43) | CTSBCTSLCTSSCTSKACE2 | |
| SCHEMBL6747821 | 0.89 | CTSL (0.39) | CTSBCTSLCTSSCTSKHPGDS | |
| SCHEMBL6752289 | 0.88 | CTSL (0.40) | CTSBCTSLCTSSCTSKHPGDS | |
| SCHEMBL6749648 | 0.87 | TRPV1 (0.45) | CTSBCTSLCTSSCTSKHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1362042-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002057249-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSB 85/4885CTSL 23/4885CTSS 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.